文献速递免疫规划慢病防控与筛查

2024-2025季BNT162b2 KP.2新冠疫苗效果:两州疫苗登记与理赔数据队列研究

2024-2025 BNT162b2 KP.2 COVID-19 full season vaccine effectiveness from vaccine registries linked to administrative claims in two states: A cohort study in non-immunocompromised adults.
PubMed 文献 · Vaccine · 2026-08-13

基于路易斯安那与加州保险理赔关联疫苗登记的回顾性队列,纳入6,256,421名非免疫抑制成人,估计2024-2025季BNT162b2 KP.2疫苗对新冠相关住院、急诊和紧急门诊的就诊保护效果。全程接种对住院的疫苗有效性(VE)为37%,对急诊/紧急门诊为12%,对急诊/紧急门诊/住院合计为16%,各年龄组及基础疾病(UMC)状态结果相似,支持继续接种推荐。

要点

  • 全程接种对新冠相关住院VE为37%,对急诊/紧急门诊为12%。
  • 对急诊/紧急门诊/住院合计VE为16%,各年龄组与UMC状态结果相似。
  • 接种者急诊、紧急门诊或住院新冠相关就诊率低于未接种者(25.1 vs 36.3/10万人月)。

核心结论

  • 2024-2025呼吸道病毒季期间,BNT162b2对非免疫抑制美国成人(含UMC者)新冠相关急诊、紧急门诊或住院提供保护,支持继续接种推荐。

研究设计与样本

  • 回顾性队列研究,基于HealthVerity理赔数据库关联两州疫苗登记,纳入路易斯安那与加州非免疫抑制成人6,256,421人,自2024年8月22日起有≥1年连续参保。

主要发现

  • 队列中330,565人(5%)接种BNT162b2,接种者年龄更大、合并症与既往流感疫苗接种更多。
  • 总体66%有≥1种UMC,最常见为肥胖(25%)、免疫抑制病史(23%)与精神健康疾病(19%)。
  • 接种者新冠相关急诊、紧急门诊或住院就诊率为25.1/10万人月,低于未接种者的36.3/10万人月。

关键数值与推荐

  • 全部成人VE:住院37%,急诊/紧急门诊12%,急诊/紧急门诊/住院合计16%。
  • 分层包括≥65岁、18-64岁伴UMC及18-64岁无UMC,结果与总体相似。

临床怎么用

  • 可向非免疫抑制成人(含基础疾病者)说明本季疫苗对住院与急诊就诊的残余保护,支持继续按推荐接种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on effectiveness of COVID-19 vaccinations during the 2024-2025 respiratory season are limited, particularly among those with underlying medical conditions (UMC). We estimated BNT162b2 KP.2 vaccine effectiveness (VE) against COVID-19-associated hospital admission, emergency department (ED), and urgent care (UC) visits in two U.S. states. METHODS: Retrospective cohort study of non-immunocompromised adults living in Louisiana or California, with ≥1 year prior continuous enrollment in insurance plans contributing to the HealthVerity claims database beginning August 22, 2024. The effectiveness of BNT162b2 KP.2 vaccine (2024-2025 formulation, hereafter referred to as BNT162b2), measured as a time-varying exposure against hospital admission, ED, or UC encounters with International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code U07.1 was calculated as 1 - adjusted hazard ratio using Cox proportional hazard models adjusted for age group, sex, state, insurance payor, presence or absence of UMCs, and pre-index healthcare utilization. Stratifications included those aged 65 years and older, those aged 18-64 years with UMCs, and those aged 18-64 years without UMCs. RESULTS: The cohort included 6,256,421 individuals (93% California, 7% Louisiana); 330,565 (5%) received the BNT162b2 vaccine. Vaccinated individuals were older and had more comorbidities, wellness visits, and prior influenza vaccination. Overall, 66% of the study population had ≥1 UMC; the most prevalent conditions were obesity (25%), history of immunocompromised conditions (23%), and mental health conditions (19%). COVID-19-related encounter rates for ED, UC or hospitalization were lower among vaccinated compared to unvaccinated persons (25.1 vs 36.3 per 100,000 person-months). Among all adults, VE was 37% against hospitalization, 12% against ED/UC encounters, and 16% against ED/UC/hospitalization encounters. Results were similar across age groups and UMCs. CONCLUSIONS: BNT162b2 provided protection against COVID-19-associated outcomes of ED, UC or hospitalization among non-immunocompromised U.S. adults, including those with UMCs, over the course of the 2024-2025 respiratory virus season, supporting continued vaccine recommendations. REGISTRATION: This study was posted on clinicaltrials.gov prior to analyses (NCT06923137).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ahi T, Andersen KM, Mateus JS, et al. 2024-2025 BNT162b2 KP.2 COVID-19 full season vaccine effectiveness from vaccine registries linked to administrative claims in two states: A cohort study in non-immunocompromised adults. Vaccine. 2026. PMID: 42594639. doi:10.1016/j.vaccine.2026.129009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。